Evkeeza from Regeneron was approved by the FDA in 2021 as an add-on treatment for patients aged 12 years and older with homozygous familial #hypercholesterolemia, a genetic condition that causes severely high cholesterol. Its activeingredient is evinacumab-dgnb, a monoclonalantibody produced in CHO cells acting as an angiopoietin-like 3 inhibitor.
Are you involved in R&D on monoclonal antibodies?
We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through our CHO4Tx product portfolio that allows in-house, fast, easy and efficient transient proteinexpression in CHO cells and through personalized advices and consultancies.
New Peer-Reviewed Paper in Antibodies Highlights Pfizer’s Outstanding Results with CHO 4Tx®
At the heart of this publication, entitled “A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology” and co-authored by Pfizer, Magellan Biologics, and
7 November 2025
